New treatment for active lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine called YKST02, either by itself or with another medicine (YK012), to see if it can help control active lupus. It may be an option if your lupus is not responding well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic lupus erythematosus (SLE) and your disease is active despite current treatments.
- You have tried standard lupus treatments (like steroids and other medications) for at least 12 weeks, or you cannot take them.
- If you are taking steroids, antimalarial drugs, or immunosuppressants, your dose has been stable for at least 2 to 4 weeks before starting the study.
- A blood test shows that you have lupus-related antibodies (like ANA, anti-dsDNA, or anti-Smith).
- You have not taken certain treatments for lupus, such as B-cell depleting therapies or other biologic medicines, within a specific period before joining.
- You do not have other serious health problems like uncontrolled infections, cancer, or major organ transplant history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ACE1831 for people with active systemic lupus erythematosus (lupus) whose disease has not improved with usual treatments. The goal is to see if ACE1831 can reduce lupus activity and help control symptoms.
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests a new medicine called SYS6020 given as an injection. It is for people with active lupus that hasn't improved with standard treatments. The goal is to see if it's safe and effective.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.